#stories

With a mission to improve personalized cancer diagnostics

Navignostics AG was founded in 2022 as a spin-off of the Bodenmiller lab (University of Zürich) with a clear mission: To leverage their unique tumor analysis approaches to guide personalized treatment selection for cancer patients and accelerate oncology drug development. They aim to revolutionize personalized cancer care based on their spatial single-cell proteomics analysis of tumors coupled to AI-driven software.

In fall 2022, Navignostics closed its seed financing round with a total of CHF 8.5 M including funding from the UZH Life Science Fund. With these proceeds, they are currently developing diagnostic tests for selected tumor indications with an unmet need and building partnerships with industry and clinical partners to identify novel biomarkers. In one such project, they teamed up with clinicians from the University Hospital Zurich to develop novel spatial biomarker signatures to determine the best individual first-line therapy for patients with metastatic colorectal cancer.

Learn more about the strategy behind Navignostics in this podcast interview with Prof. Bernd Bodenmiller.